Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-20. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Early in the morning (10 August 1792) 30,000 Fédérés, and sans-culottes militants from the sections led a successful assault upon the Tuileries; according to Robespierre a triumph for the "passive" (non-voting) citizens. Sulpice Huguenin, head of the sans-culottes in the Faubourg Saint-Antoine, was appointed provisional president of the Insurrectionary Commune. In Spring 1793, after the defection of Dumouriez, Robespierre urged the creation of a "sans-culotte army" to sweep away any conspirator. On 1 May, the crowds threatened armed insurrection if the emergency measures demanded (price control) were not adopted. On 8 and 12 May Robespierre repeated in the Jacobin club the necessity of founding a revolutionary army consisting of sans-culottes, paid by a tax on the rich, to beat the aristocrats inside France and the convention. Every public square should be used to produce arms and pikes. On 18 May, Marguerite-Élie Guadet proposed to examine the "exactions" and to replace municipal authorities. As rioting persisted, a commission of inquiry of twelve members, with a very strong Girondin majority, was set up to investigate the anarchy in the communes and the activities of the sans-culottes. On 28 May, the Paris Commune accepted the creation of a sans-culottes army to enforce revolutionary laws. Petitioners from the sections and the Commune appeared at the bar of the Convention at about five o'clock in the afternoon on 31 May.
The wool is left to lie in soak for five hours, and then, after carding it, it is thrown in again, until it has fully imbibed the colour. Archaeological data from Tyre indicate that the snails were collected in large vats and left to decompose. This produced a hideous stench that was mentioned by ancient authors. Not much is known about the subsequent steps, and the actual ancient method for mass-producing the two murex dyes has not yet been successfully reconstructed; this special "blackish clotted blood" colour, which was prized above all others, is believed to be achieved by double-dipping the cloth, once in the indigo dye of H. trunculus and once in the purple-red dye of B. brandaris.
=== Animal fats === Trans fatty acids (TFAs) occur in small amounts in meat and milk of ruminants (such as cattle and sheep), typically 2–5% of total fat. Natural TFAs, which include conjugated linoleic acid (CLA) and vaccenic acid, originate in the rumen of these animals. CLA has two double bonds, one in the cis configuration and one in trans, which makes it simultaneously a cis- and a trans-fatty acid. A type of trans fat occurs naturally in the milk and body fat of ruminants (such as cattle and sheep) at a level of 2–5% of total fat. The US National Dairy Council has asserted that the trans fats present in foods of animal origin are of a different type than those in partially hydrogenated oils, and do not appear to exhibit the same negative effects. A scientific review agrees with the conclusion (stating that "the sum of the current evidence suggests that the Public health implications of consuming trans fats from ruminant products are relatively limited") but cautions that this may be due to the low consumption of trans fats from animal sources compared to artificial ones. Despite this concern, the NAS dietary recommendations have not included eliminating trans fat from the diet. This is because trans fat is naturally present in many animal foods in trace quantities, and thus its removal from ordinary diets might introduce undesirable side effects and nutritional imbalances if proper nutritional planning is not undertaken. The NAS has, thus, "recommended that trans fatty acid consumption be as low as possible while consuming a nutritionally adequate diet".
=== Conditionally essential === Conditionally essential nutrients are certain organic molecules that can normally be synthesized by an organism, but under certain conditions in insufficient quantities. In humans, such conditions include premature birth, limited nutrient intake, rapid growth, and certain disease states. Inositol, taurine, arginine, glutamine and nucleotides are classified as conditionally essential and are particularly important in neonatal diet and metabolism.
Sources: en.wikipedia.org
== Case against Stephen Dank == The AFL Tribunal heard cases against sports scientist Stephen Dank during the summer of 2014/15, and he was found guilty of ten charges. The charges upheld against Dank covered a wide range of illegal supplements that he trafficked in, attempted to traffic in, or was complicit in attempted trafficking when the AFL registered him. The upheld charges were:
=== B cells === TGF-β1 has similar effects on B cells that also vary according to the differentiation state of the cell. It inhibits proliferation, stimulates apoptosis of B cells, and controls the expression of antibody, transferrin and MHC class II proteins on immature and mature B cells.
== Safety and regulation == Active packaging is designed to interact with the packaged product or the surrounding environment. The active function does not remove the requirement for the underlying packaging to comply with applicable food-contact, pharmaceutical, transport, environmental, and product-safety rules. In the European Union, Commission Regulation (EC) No 450/2009 establishes specific requirements for active and intelligent materials intended to come into contact with food. It defines active materials as materials designed to deliberately release or absorb substances in order to extend shelf life or maintain or improve food condition. Substances intended to migrate into food may also be subject to food-additive and labelling requirements. Components positioned behind a functional barrier must remain within applicable migration limits. Intelligent packaging must not provide misleading information about the condition or safety of a product. An indicator that makes spoiled food appear acceptable could create a safety risk. Safety assessment may include:
=== Personal life and death === Dyson married his first wife, the Swiss mathematician Verena Huber, on 11 August 1950. They had two children, Esther and George, before divorcing in 1958. In November 1958 he married Imme Jung, with whom he had four daughters. Dyson died on 28 February 2020 at Penn Medicine Princeton Medical Center in Plainsboro Township, New Jersey, from complications following a fall. He was 96.
=== Insulin === Some guidelines recommend a bolus (initial large dose) of insulin of 0.1 units of insulin per kilogram of body weight. This can be administered immediately after the potassium level is known to be higher than 3.3 mmol/L; if the level is any lower, administering insulin could lead to a dangerously low potassium level (see below). Other guidelines recommend a bolus given intramuscularly if there is a delay in commencing an intravenous infusion of insulin, whereas guidelines for the management of pediatric DKA recommend delaying the initiation of insulin until fluids have been administered. It is possible to use rapid acting insulin analog injections under the skin for mild or moderate cases. In general, insulin is given at 0.1 units/kg per hour to reduce blood sugars and suppress ketone production. Guidelines differ as to which dose to use when blood sugar levels start falling; American guidelines recommend reducing the dose of insulin once glucose falls below 16.6 mmol/L (300 mg/dL) and UK guidelines at 14 mmol/L (253 mg/dL). Others recommend infusing glucose in addition to saline to allow for ongoing infusion of higher doses of insulin.
Sources: en.wikipedia.org
=== FDA-approved === In 2019, the FDA approved the first drug targeting melanocortin receptors, Vyleesi (Bremelanotide) which was developed by Palatin Technologies, Inc. The Melanocortin system has been largely unexplored in drug development but recent approvals, its novelty and wide-spread application across indications has led it to the frontier of new discoveries in medicine. Since Vyleesi approval multiple companies have initiated drug discovery programs targeting the melanocortin system. Bremelanotide (Vyleesi) is approved for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. At therapeutic dose levels, it activates MC1R and MC4R. Setmelanotide (Imcivree) is an MC4R agonist approved for chronic weight management in patients with genetic obesity. Afamelanotide (Scenesse) is an MC1R agonist approved for patients with erythropoietic protoporphyria to increase pain-free light exposure.
==== Antifungals ==== Regular use of an over-the-counter or prescription antifungal shampoo or cream is a common treatment. The topical antifungal medications ketoconazole and ciclopirox have the best evidence. Ketoconazole should be used twice per week. Shampoo or soap containing zinc pyrithione, selenium disulfide, or piroctone olamine is also used. Products containing zinc pyrithione have been banned in the European Union since 2021 due to concerns over environmental toxicity alongside the presence of suitable alternatives. These options are often used daily and may also be used in conjunction with a ketoconazole shampoo regimen on alternate days. It is unclear if other antifungals are equally effective, as this has not been sufficiently studied. Antifungals that have been studied and found to be effective in the treatment of seborrhoeic dermatitis include ketoconazole, fluconazole, miconazole, bifonazole, sertaconazole, clotrimazole, flutrimazole, ciclopirox, terbinafine, butenafine, selenium disulfide, piroctone olamine and lithium salts such as lithium gluconate and lithium succinate. Topical climbazole appears to have little effectiveness in the treatment of seborrhoeic dermatitis. Systemic therapy with oral antifungals including itraconazole, fluconazole, ketoconazole is effective. Adverse side effects have been documented for fluconazole and ketoconazole, with the latter not recommended for use, while itraconazole, with its good safety profile, is the most commonly prescribed.
=== Pulmonary and tricuspid valve disorders === Pulmonary and tricuspid valve diseases are right heart diseases. Pulmonary valve diseases are the least common heart valve disease in adults. Pulmonary valve stenosis is often the result of congenital malformations and is observed in isolation or as part of a larger pathologic process, as in Tetralogy of Fallot, Noonan syndrome, and congenital rubella syndrome. Unless the degree of stenosis is severe, individuals with pulmonary stenosis usually have excellent outcomes and better treatment options. Often patients do not require intervention until later in adulthood as a consequence of calcification that occurs with aging. Pulmonary valve insufficiency occurs commonly in healthy individuals to a very mild extent and does not require intervention. More appreciable insufficiency is typically the result of damage to the valve due to cardiac catheterization, intra-aortic balloon pump insertion, or other surgical manipulations. Additionally, insufficiency may be the result of carcinoid syndrome, inflammatory processes such a rheumatoid disease or endocarditis, or congenital malformations. It may also be secondary to severe pulmonary hypertension. Tricuspid valve stenosis without co-occurrent regurgitation is highly uncommon and typically the result of rheumatic disease. It may also be the result of congenital abnormalities, carcinoid syndrome, obstructive right atrial tumors (typically lipomas or myxomas), or hypereosinophilic syndromes. Minor tricuspid insufficiency is common in healthy individuals.
=== Antimicrobials === Aminoglycosides — an antibacterial; its use is extremely restricted due to risk of hearing loss and kidney damage. Amphotericin B — used for life-threatening fungal infections and primary amoebic meningoencephalitis; its side effects are often severe or potentially fatal. Carbapenems (such as imipenem/cilastatin) — used as a drug of last resort for a variety of different bacterial infections; use is limited to prevent development of drug resistance. Ceftobiprole and ceftaroline — fifth-generation cephalosporins active against methicillin-resistant Staphylococcus aureus (MRSA); use is limited to prevent development of drug resistance. Cefiderocol — a cephalosporin used to treat complicated urinary tract infections (cUTI) caused by multi-drug resistant Gram-negative bacteria in patients with limited or no alternative options; use is limited for other MDRGN bacteria since its safety and efficacy have not been established. Chloramphenicol — formerly first-line therapy for Rocky Mountain spotted fever (until doxycycline became available), current first-line therapy (topically) for bacterial conjunctivitis, and (systemically) for meningitis when allergies to penicillin or cephalosporin exist; use of intravenous chloramphenicol carries unacceptably high risk of irreversible, fatal aplastic anemia and gray baby syndrome. Colistin — used against certain life-threatening infections, such as those caused by Pseudomonas; carries risk of kidney and nerve damage.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.